

Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Currently Amended). A compound comprising two individual peptide sequences, each sequence independently having a length of between 6 to 20 amino acids, wherein at least one of the two individual peptide sequences comprises an amino acid sequence ~~of the formula (I)~~ selected from the group consisting of SEQ ID NO:1; SEQ ID NO:2, contiguous fragments of SEQ ID NO:1 having at least 40% of the length of said sequence, and contiguous fragments of SEQ ID NO:2 having at least 40% of the length of said sequence, and

~~L1-A-L2-B-L3-C-L4-D-L5~~

wherein

~~one of A, B, C, D is selected from a hydrophobic amino acid residue,~~

~~one of A, B, C, D is selected from a basic amino acid residue, Asn or Gln,~~

~~one of A, B, C, D is selected from an acidic amino acid residue, Asn or Gln,~~

~~one of A, B, C, D is Gly or Ala, and~~

~~L1, L2, L3, L4 and L5 is selected from a chemical bond or an amino acid sequence having n amino acid residues, wherein n is an integer of from 0 to 5,~~

wherein

said two peptide sequences are connected to each other through a linker of the formula ~~(II)~~

$$X[(A)_n\text{COOH}][(B)_m\text{COOH}]$$

n and m independently are an integer of from 1 to 20,

X is HN, H₂N(CR₂)_pCR, RHN(CR₂)_pCR, HO(CR₂)_pCR, HS(CR₂)_pCR,

halogen-(CR₂)_pCR, HOOC(CR₂)_pCR, ROOC(CR₂)_pCR, HCO(CR₂)_pCR, RCO(CR₂)_pCR, [HOOC(A)_n][HOOC(B)_m]CR(CR₂)_pCR, H₂N(CR₂)_p, RHN(CR₂)_p, HO(CR₂)_p, HS(CR₂)_p, halogen-(CR₂)_p, HOOC(CR₂)_p, ROOC(CR₂)_p, HCO(CR₂)_p, RCO(CR₂)_p, or [HOOC(A)_n][HOOC(B)_m](CR₂)_p, wherein p is 0 or integer of from 1 to 20, A and B independently are a substituted or unsubstituted C₁₋₁₀ alkyl, a substituted or unsubstituted C₂₋₁₀ alkenyl, a substituted or unsubstituted cyclic moiety, a substituted or unsubstituted heterocyclic moiety, a substituted or unsubstituted aromatic moiety, or A and B together form a substituted or unsubstituted cyclic moiety, substituted or unsubstituted heterocyclic moiety, or substituted or unsubstituted aromatic moiety.

wherein said two individual peptide sequences ~~of formula (I)~~ and said compound are capable of binding to a receptor selected from the family of fibroblast growth factor receptors (FGFRs) consisting of FGFR1, FGFR2, FGFR3, and FGFR4.

2-10 (Cancelled).

11 (Currently Amended). The compound according to claim 1, wherein the at least one of the two peptide sequences consists of an amino acid sequence selected from the group consisting of

EVYVVAENQQGKSKA (SEQ ID NO 1), and
NIEVWVEAENALGKKV (SEQ ID NO: 2) [[,]]
~~ATNRQGGKVKAF AHL (SEQ ID NO: 3),~~
~~RYVELYVVADSQEFQK (SEQ ID NO: 4)~~
~~VAENSRGKNVAKG (SEQ ID NO: 5),~~
~~GEYWCVAENQYGQR (SEQ ID NO: 6),~~
~~RLAALNGKGLGEIS (SEQ ID NO: 7),~~
~~KYIAENMKAQNVAK EI (SEQ ID NO: 8),~~
~~EIWVEATNRLG (SEQ ID NO: 13),~~
~~EVWIEKDPKGR I (SEQ ID NO: 15),~~

~~ATNKGGEVKKNGHL (SEQ ID NO: 16),~~
~~KYVELYLVADYLEFQK (SEQ ID NO: 17),~~
~~RYVELYVVVDNAEFQ (SEQ ID NO: 18),~~
~~KYVELVIVADNREFQR (SEQ ID NO: 19),~~
~~KYIEYYLVLDNGEFKR (SEQ ID NO: 20),~~
~~RYLELYIVADHTLF (SEQ ID NO: 21),~~
~~KYVELFIVADDTVYRR (SEQ ID NO: 24),~~
~~KFIELFVVADEYVYRR (SEQ ID NO: 25),~~
~~KIVEKVIVADNSEVRK (SEQ ID NO: 26),~~
~~VELVIVADHSEAQK (SEQ ID NO: 27),~~
~~VAENSRGKNIAKG (SEQ ID NO: 28),~~
~~IAENSRGKNVARG (SEQ ID NO: 29),~~
~~AENSRGKNSFRG (SEQ ID NO: 30),~~
~~IASNLGRGNLAKG (SEQ ID NO: 31),~~
~~IPENSLGKTYAKG (SEQ ID NO: 32),~~
~~IAENMKAQNEAK (SEQ ID NO: 33),~~
~~QFIAENMKSHNETKEV (SEQ ID NO: 34),~~
~~GEYWCVAKNRVGQ (SEQ ID NO: 35),~~
~~GSYTCVAENMVGK (SEQ ID NO: 36),~~
~~GKYVCVGTNMVGER (SEQ ID NO: 37),~~
~~GEYQCFARNDYG (SEQ ID NO: 47),~~
~~GEYFCLASNKMG (SEQ ID NO: 48),~~
~~GEYQCFARNKFG (SEQ ID NO: 49),~~
~~GEYFCLASNKMG (SEQ ID NO: 50),~~
~~GNYSCEAENAWGTK (SEQ ID NO: 52),~~
~~GEYECVAENGRLG (SEQ ID NO: 54),~~
~~GNYTECVVENKFGR (SEQ ID NO: 55),~~
~~GMYQCVAENKHLG (SEQ ID NO: 59),~~
~~G DYTLIAKNEYGK (SEQ ID NO: 62),~~
~~GKYE CVATNSAGTR (SEQ ID NO: 64),~~
~~GEYECAATNAHGR (SEQ ID NO: 66),~~
~~GAYWCQGTNSVGK (SEQ ID NO: 67),~~
~~RVA AVNGKGQGDYS (SEQ ID NO: 69),~~
~~RVA AINGCGIGPFS (SEQ ID NO: 70),~~
~~AVLNGKGLG (SEQ ID NO: 71),~~

~~RLAAKNRAGLGE (SEQ ID NO: 73),~~
~~GNYSCLAENRLGR (SEQ ID NO: 97),~~
~~GTTHCVATNAHG (SEQ ID NO: 99),~~
~~HLEVQAFNGRGSQPA (SEQ ID NO: 114),~~
~~HLTVRAYNGAGYGP (SEQ ID NO: 115),~~
~~HLSVKAYNSAGTGPS (SEQ ID NO: 116),~~
~~HLAVKAYNSAGTGPS (SEQ ID NO: 117),~~
~~NLEVRAFNSAGDGP (SEQ ID NO: 118),~~
~~HLTVLAYNSKQAGP (SEQ ID NO: 119),~~
~~LRVLVFNNGRGDGP (SEQ ID NO: 120),~~
~~HIDVSAFNSAGYGP (SEQ ID NO: 121),~~
~~HLAVELFNNGR (SEQ ID NO: 122),~~
~~LLELQSINFLGGQPA (SEQ ID NO: 123),~~
~~HFTVRAYNGAGYGP (SEQ ID NO: 124),~~
~~HLEVQAFNGRGSQPA (SEQ ID NO: 125),~~
~~EVRVQAVNGGGNGPP (SEQ ID NO: 137),~~
~~LIKVVAINDRGE (SEQ ID NO: 138),~~
~~VVSIIAVNGREE (SEQ ID NO: 139),~~
~~VVSVYAQNQNGE (SEQ ID NO: 140),~~
~~TISLVAEKGRHK (SEQ ID NO: 141),~~
~~HLEVQAFNGRGSQPA (SEQ ID NO: 142),~~
~~HVEVQAFNGRGLGPA (SEQ ID NO: 143),~~
~~HVEVQAFNGRGLGPA (SEQ ID NO: 144), and~~
~~EFRVRAVNGAGEG (SEQ ID NO: 145).~~

12 (Previously Presented). The compound according to claim 1, wherein the at least one of the two peptide sequences is SEQ ID NO: 1 (EVYVVAENQQGKSKA).

13 (Cancelled).

14 (Previously Presented). The compound according to claim 1, wherein the at least one of the two peptide sequences is SEQ ID NO: 2 (NIEVWVEAENALGKKV).

15-16 (Cancelled)

17 (Currently Amended). The compound according to claim ~~16~~ 1, wherein ~~the both individual peptide fragments sequences~~ consist of the sequence EVYVVAENQQGKSKA (SEQ ID NO: 1).

18 (Currently Amended). The compound according to claim ~~16~~ 1, wherein ~~the both individual peptide fragments sequences~~ consist of the sequence NIEVWVEAENALGKKV (SEQ ID NO: 2).

19 (Currently Amended). The compound according to claim ~~15~~ 1, wherein one of the two individual peptide fragments sequences consists of the sequence EVYVVAENQQGKSKA (SEQ ID NO: 1), and the other consists of the sequence NIEVWVEAENALGKKV (SEQ ID NO: 2).

20 (Currently Amended). The compound according to claim 11, said compound being obtained by a method comprising the steps of
providing by solid phase synthesis or fragment coupling ligands comprising desired sequence(s), the ligands being attached to a solid phase,
if ~~nessesary~~ necessary, deprotecting any N-terminal amino acid groups while the ligand(s) are still attached to the solid phase, reacting the ligand(s) having unprotected N-terminal groups with an achiral di- tri- or tetracarboxylic acid so as to provide a construct having a ring structure, and
cleaving the construct from the solid phase so as to provide ~~an LPA~~ a ligand presenting assembly (LPA) comprising ligands having free C-terminal groups.

21 (Previously Presented). A pharmaceutical composition comprising a compound as defined in claim 1.

22 (Withdrawn). Method of treatment comprising administering

an effective amount of a compound as defined in claim 1 for treatment of conditions of the central and peripheral nervous system associated with postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic damage, Parkinson's disease, Alzheimer's disease, Huntington's disease, dementias, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia, mood disorders; for treatment of diseases or conditions of the muscles; or for treatment of diseases or conditions of the gonads, pancreas, kidney, heart, liver or bowel.

23 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the treatment of postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic damage, Parkinson's disease, Alzheimer's disease, Huntington's disease, dementias, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, schizophrenia, or mood disorders.

24 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the promotion of wound-healing.

25 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the treatment of cancer.

26 (Withdrawn). The method of treatment according to claim 25, wherein the cancer is any type of solid tumor requiring neoangiogenesis.

27 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the prevention of death of heart muscle cells.

28 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for revascularization.

29 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the stimulation of the ability to learn and/or the short and/or long-term memory.

30 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the prevention of cell death due to ischemia.

31 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the prevention of body damage due to alcohol consumption.

32 (Withdrawn). Method of treatment comprising administering an effective amount of a compound as defined in claim 1 for the treatment of prion diseases.

33-34 (Cancelled).

35 (Currently Amended). The compound according to claim ~~16~~ 1, wherein ~~the both individual peptide fragments each sequences~~ comprise the sequence EVYVVAENQQGKSKA (SEQ ID NO: 1).

36 (Currently Amended). The compound according to claim ~~16~~ 1, wherein ~~the both individual peptide fragments each sequences~~ comprise the sequence NIEVWVEAENALGKKV (SEQ ID NO: 2).

USSN - 10/567,365

37-38 (Cancelled).

39 (Previously Presented). The compound of claim 1 wherein the at least one peptide sequence comprises at least 9 consecutive amino acids of SEQ ID NO:1 or SEQ ID NO:2.

40-49 (Cancelled).